CN104334540B - 二甲基-苯甲酸化合物 - Google Patents
二甲基-苯甲酸化合物 Download PDFInfo
- Publication number
- CN104334540B CN104334540B CN201380030138.XA CN201380030138A CN104334540B CN 104334540 B CN104334540 B CN 104334540B CN 201380030138 A CN201380030138 A CN 201380030138A CN 104334540 B CN104334540 B CN 104334540B
- Authority
- CN
- China
- Prior art keywords
- dimethyl
- amino
- benzoic acid
- methyl
- under reduced
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 Cc(cc1)c(*)c(C)c1C(OC)=O Chemical compound Cc(cc1)c(*)c(C)c1C(OC)=O 0.000 description 8
- REFIOUTVFHKRSL-UHFFFAOYSA-N CC(C)(C)[Si](C)(C)OC(CC1)CCN1c1cc(cccc2)c2c(C(Nc2c(C)c(C(OC)=O)ccc2C)=O)c1 Chemical compound CC(C)(C)[Si](C)(C)OC(CC1)CCN1c1cc(cccc2)c2c(C(Nc2c(C)c(C(OC)=O)ccc2C)=O)c1 REFIOUTVFHKRSL-UHFFFAOYSA-N 0.000 description 1
- GCPNPVFWMHBPNS-UHFFFAOYSA-N CC(C)(C)[Si](C)(C)OC1CCNCC1 Chemical compound CC(C)(C)[Si](C)(C)OC1CCNCC1 GCPNPVFWMHBPNS-UHFFFAOYSA-N 0.000 description 1
- ICWFOUBIQGJWEJ-UHFFFAOYSA-N CCC(c1c(C)c(N)c(C)cc1)=O Chemical compound CCC(c1c(C)c(N)c(C)cc1)=O ICWFOUBIQGJWEJ-UHFFFAOYSA-N 0.000 description 1
- OBPBIINVJRPUQI-UHFFFAOYSA-N CCOC1OC1c(cc1C)cc(C)c1NC(C(C(C)=CC1)=NC1N(CC1)CCC1[O]=[Si](C)(C)(CC)C(C)C)=O Chemical compound CCOC1OC1c(cc1C)cc(C)c1NC(C(C(C)=CC1)=NC1N(CC1)CCC1[O]=[Si](C)(C)(CC)C(C)C)=O OBPBIINVJRPUQI-UHFFFAOYSA-N 0.000 description 1
- XOIKXWDCCNJCQH-UHFFFAOYSA-N Cc(c(C(C=C)=O)c1)ccc1Br Chemical compound Cc(c(C(C=C)=O)c1)ccc1Br XOIKXWDCCNJCQH-UHFFFAOYSA-N 0.000 description 1
- BVLDTCPPYOKJCV-UHFFFAOYSA-N Cc(cc1)c(C(Nc2c(C)ccc(C(O)=O)c2C)=O)nc1N1CC(CO)CCC1 Chemical compound Cc(cc1)c(C(Nc2c(C)ccc(C(O)=O)c2C)=O)nc1N1CC(CO)CCC1 BVLDTCPPYOKJCV-UHFFFAOYSA-N 0.000 description 1
- JLLLNXJTBCOQFL-UHFFFAOYSA-N Cc(cc1)c(C(Nc2c(C)ccc(C(OC)=O)c2C)=O)nc1Cl Chemical compound Cc(cc1)c(C(Nc2c(C)ccc(C(OC)=O)c2C)=O)nc1Cl JLLLNXJTBCOQFL-UHFFFAOYSA-N 0.000 description 1
- BVJCJNHJXYDZTC-UHFFFAOYSA-N Cc(ccc(C(O)=O)c1C)c1NC(C(C1)C(F)=CC=C1N1CC(CO)CCC1)=O Chemical compound Cc(ccc(C(O)=O)c1C)c1NC(C(C1)C(F)=CC=C1N1CC(CO)CCC1)=O BVJCJNHJXYDZTC-UHFFFAOYSA-N 0.000 description 1
- NEOTWVWYOFULFP-UHFFFAOYSA-N Cc(ccc(C(OC)=O)c1C)c1NC(C(C1)C(F)=CC=C1N1CC(CO)CCC1)=O Chemical compound Cc(ccc(C(OC)=O)c1C)c1NC(C(C1)C(F)=CC=C1N1CC(CO)CCC1)=O NEOTWVWYOFULFP-UHFFFAOYSA-N 0.000 description 1
- GOEASVSGVVOTLQ-UHFFFAOYSA-N Cc1cc(C(N)=O)c(C)cc1 Chemical compound Cc1cc(C(N)=O)c(C)cc1 GOEASVSGVVOTLQ-UHFFFAOYSA-N 0.000 description 1
- KFQPHKLTAJLUCZ-UHFFFAOYSA-N Cc1ccc(C(OC)=O)c(C)c1NC(c1cc([Br]=C)cc2c1cccc2)=O Chemical compound Cc1ccc(C(OC)=O)c(C)c1NC(c1cc([Br]=C)cc2c1cccc2)=O KFQPHKLTAJLUCZ-UHFFFAOYSA-N 0.000 description 1
- ZOPJGFHJDZGOQP-UHFFFAOYSA-N Cc1ccc(C)c([N+]([O-])=O)c1C Chemical compound Cc1ccc(C)c([N+]([O-])=O)c1C ZOPJGFHJDZGOQP-UHFFFAOYSA-N 0.000 description 1
- HDFQKJQEWGVKCQ-UHFFFAOYSA-N Cc1cccc(C)c1[N+]([O-])=O Chemical compound Cc1cccc(C)c1[N+]([O-])=O HDFQKJQEWGVKCQ-UHFFFAOYSA-N 0.000 description 1
- SBGVNBGHCCLMRR-UHFFFAOYSA-N OC(c1cc(Br)cc2ccccc12)=O Chemical compound OC(c1cc(Br)cc2ccccc12)=O SBGVNBGHCCLMRR-UHFFFAOYSA-N 0.000 description 1
- BIWOSRSKDCZIFM-UHFFFAOYSA-N OC1CNCCC1 Chemical compound OC1CNCCC1 BIWOSRSKDCZIFM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/42—Oxygen atoms attached in position 3 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261665956P | 2012-06-29 | 2012-06-29 | |
| US61/665,956 | 2012-06-29 | ||
| US201361778969P | 2013-03-13 | 2013-03-13 | |
| US61/778,969 | 2013-03-13 | ||
| PCT/US2013/046685 WO2014004230A1 (en) | 2012-06-29 | 2013-06-20 | Dimethyl-benzoic acid compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104334540A CN104334540A (zh) | 2015-02-04 |
| CN104334540B true CN104334540B (zh) | 2016-03-16 |
Family
ID=48746667
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201380030138.XA Expired - Fee Related CN104334540B (zh) | 2012-06-29 | 2013-06-20 | 二甲基-苯甲酸化合物 |
Country Status (40)
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110015221A1 (en) * | 2003-12-23 | 2011-01-20 | Pierre Fabre Medicament | Pharmaceutical composition of vinflunine which is intended for parenteral administration preparation method thereof and use of same |
| TWI572597B (zh) * | 2012-06-29 | 2017-03-01 | 美國禮來大藥廠 | 二甲基－苯甲酸化合物 |
| EP2765128A1 (en) * | 2013-02-07 | 2014-08-13 | Almirall, S.A. | Substituted benzamides with activity towards EP4 receptors |
| TWI636046B (zh) | 2013-05-17 | 2018-09-21 | 美國禮來大藥廠 | 苯氧基乙基二氫－１ｈ－異喹啉化合物 |
| ES2727329T3 (es) | 2013-12-17 | 2019-10-15 | Lilly Co Eli | Compuestos de ácido dimetilbenzoico |
| CA2960324A1 (en) * | 2014-09-09 | 2016-03-17 | Bayer Pharma Aktiengesellschaft | Substituted n,2-diarylquinoline-4-carboxamides and the use thereof as anti-inflammatory agents |
| CR20180323A (es) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
| EA201992386A1 (ru) * | 2017-04-10 | 2020-03-27 | Байер Акциенгезельшафт | Замещенные n-арилэтил-2-арилхинолин-4-карбоксамиды и их применение |
| TWI770157B (zh) * | 2017-04-10 | 2022-07-11 | 德商拜耳廠股份有限公司 | 經取代之n-芳基乙基-2-胺基喹啉-4-甲醯胺及其用途 |
| AR111808A1 (es) | 2017-05-18 | 2019-08-21 | Idorsia Pharmaceuticals Ltd | Derivados de pirimidina como moduladores del receptor de pge2 |
| EP3625227B1 (en) | 2017-05-18 | 2022-09-14 | Idorsia Pharmaceuticals Ltd | Benzofurane and benzothiophene derivatives as pge2 receptor modulators |
| WO2018210992A1 (en) | 2017-05-18 | 2018-11-22 | Idorsia Pharmaceuticals Ltd | Pyrimidine derivatives |
| SI3625222T1 (sl) | 2017-05-18 | 2021-11-30 | Idorsia Pharmaceuticals Ltd | Derivati fenila kot modulatorji receptorja pge2 |
| TWI768043B (zh) | 2017-05-18 | 2022-06-21 | 瑞士商愛杜西亞製藥有限公司 | N-取代吲哚衍生物 |
| EP4245301A4 (en) | 2020-11-13 | 2024-08-21 | ONO Pharmaceutical Co., Ltd. | TREATMENT OF CANCER BY COMBINED USE OF AN EP4 ANTAGONIST AND AN IMMUNE CHECKPOINT INHIBITOR |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1270615B (it) | 1994-07-14 | 1997-05-07 | Smithkline Beecham Farma | Uso di derivati di chinolina |
| JP2000355551A (ja) * | 1999-06-15 | 2000-12-26 | Nikken Chem Co Ltd | 医薬組成物 |
| WO2005030753A2 (en) | 2003-09-22 | 2005-04-07 | Euro-Celtique S.A. | Therapeutic agents useful for treating pain |
| WO2005080367A1 (en) | 2004-02-12 | 2005-09-01 | Pharmagene Laboratories Limited | Ep2 receptor agonists |
| EP2035376B1 (en) * | 2006-06-12 | 2014-08-27 | Merck Canada Inc. | Indoline amide derivatives as ep4 receptor ligands |
| US8030489B2 (en) * | 2007-03-26 | 2011-10-04 | Astellas Pharma Inc. | Ornithine derivative |
| WO2012004293A2 (de) | 2010-07-08 | 2012-01-12 | Bayer Cropscience Ag | Insektizide und fungizide wirkstoffkombinationen |
| US20140057953A1 (en) | 2011-03-03 | 2014-02-27 | Rolf Hartmann | Biaryl derivatives as selective 17beta-hydroxysteroid dehydrogenase type 2 inhibitors |
| TWI572597B (zh) * | 2012-06-29 | 2017-03-01 | 美國禮來大藥廠 | 二甲基－苯甲酸化合物 |
-
2013
- 2013-06-11 TW TW102120796A patent/TWI572597B/zh not_active IP Right Cessation
- 2013-06-13 JO JOP/2013/0178A patent/JO3221B1/ar active
- 2013-06-13 AR ARP130102078 patent/AR091431A1/es unknown
- 2013-06-20 AP AP2014008165A patent/AP4063A/en active
- 2013-06-20 ME MEP-2017-83A patent/ME02655B/me unknown
- 2013-06-20 BR BR112014029551A patent/BR112014029551A2/pt not_active IP Right Cessation
- 2013-06-20 HU HUE13734249A patent/HUE032398T2/en unknown
- 2013-06-20 PE PE2014002531A patent/PE20150185A1/es active IP Right Grant
- 2013-06-20 CN CN201380030138.XA patent/CN104334540B/zh not_active Expired - Fee Related
- 2013-06-20 DK DK13734249.9T patent/DK2867218T3/en active
- 2013-06-20 SG SG11201408629QA patent/SG11201408629QA/en unknown
- 2013-06-20 EA EA201492140A patent/EA025531B1/ru not_active IP Right Cessation
- 2013-06-20 WO PCT/US2013/046685 patent/WO2014004230A1/en not_active Ceased
- 2013-06-20 KR KR1020147036136A patent/KR101634032B1/ko not_active Expired - Fee Related
- 2013-06-20 HR HRP20170540TT patent/HRP20170540T1/hr unknown
- 2013-06-20 AU AU2013280779A patent/AU2013280779B2/en not_active Ceased
- 2013-06-20 MX MX2014015952A patent/MX347476B/es active IP Right Grant
- 2013-06-20 PL PL13734249T patent/PL2867218T3/pl unknown
- 2013-06-20 CA CA2875572A patent/CA2875572C/en not_active Expired - Fee Related
- 2013-06-20 LT LTEP13734249.9T patent/LT2867218T/lt unknown
- 2013-06-20 ES ES13734249.9T patent/ES2623099T3/es active Active
- 2013-06-20 NZ NZ701894A patent/NZ701894A/en not_active IP Right Cessation
- 2013-06-20 MY MYPI2014703973A patent/MY172860A/en unknown
- 2013-06-20 RS RS20170231A patent/RS55756B1/sr unknown
- 2013-06-20 EP EP13734249.9A patent/EP2867218B1/en active Active
- 2013-06-20 PT PT137342499T patent/PT2867218T/pt unknown
- 2013-06-20 JP JP2015520305A patent/JP6114824B2/ja active Active
- 2013-06-20 SI SI201330576A patent/SI2867218T1/sl unknown
- 2013-06-20 IN IN2356MUN2014 patent/IN2014MN02356A/en unknown
- 2013-06-20 US US13/922,277 patent/US8642768B2/en not_active Expired - Fee Related
- 2013-12-04 US US14/096,469 patent/US8933098B2/en not_active Expired - Fee Related
-
2014
- 2014-11-24 ZA ZA2014/08631A patent/ZA201408631B/en unknown
- 2014-11-28 TN TN2014000500A patent/TN2014000500A1/fr unknown
- 2014-12-03 CR CR20140554A patent/CR20140554A/es unknown
- 2014-12-11 IL IL236218A patent/IL236218A/en active IP Right Grant
- 2014-12-17 DO DO2014000286A patent/DOP2014000286A/es unknown
- 2014-12-17 GT GT201400289A patent/GT201400289A/es unknown
- 2014-12-18 CO CO14278424A patent/CO7160064A2/es unknown
- 2014-12-26 CL CL2014003537A patent/CL2014003537A1/es unknown
-
2015
- 2015-01-05 PH PH12015500008A patent/PH12015500008A1/en unknown
-
2017
- 2017-04-12 CY CY20171100435T patent/CY1118830T1/el unknown
Non-Patent Citations (1)
| Title |
|---|
| Discovery of 4-{1-[({1-[4-(trifluoromethyl)benzyl]-1H-indol-7-yl}carbonyl）amino]cyclopropyl}benzoic acid (MF-766), a highly potent and selective EP4 antagonist for treating inflammatory pain;John Colucci et.al.;《Bioorganic & Medicinal Chemistry Letters》;20100418;第20卷;3760-3763 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104334540B (zh) | 二甲基-苯甲酸化合物 | |
| CN104411684B (zh) | 苯氧基乙基哌啶化合物 | |
| TWI691488B (zh) | ３,４-二氫異喹啉-２（１ｈ）-基化合物 | |
| CN106459017B (zh) | 作为可溶性鸟苷酸环化酶活化剂的杂环羧酸 | |
| MXPA01011976A (es) | Derivados de tipo indol como inhibidores de cinasa p38. | |
| CN106715418A (zh) | 治疗化合物及其使用方法 | |
| CN101151244B (zh) | 组胺h3受体活性剂、制备和治疗用途 | |
| CN108430969B (zh) | 杂环取代的n-磺酰基苯甲酰胺衍生物、其制法与医药上的用途 | |
| TW201443004A (zh) | 苯氧基乙氧基化合物 | |
| TW201534588A (zh) | 苯氧基乙基二氫－１ｈ－異喹啉化合物 | |
| WO2019062848A1 (zh) | N-(取代磺酰基)苯甲酰胺类衍生物及其制备方法和医药用途 | |
| CN108137515A (zh) | 羟基三嗪化合物和其医药用途 | |
| WO2016088903A1 (en) | Heterocyclic compounds | |
| CN105693817B (zh) | 一类三肽化合物及其制备方法与应用 | |
| RS51358B (sr) | Derivati n-(heteroaril)-1h-indol-2-karboksamida i njihova upotreba kao liganda vaniloidnog trpv1 receptora | |
| TW201014847A (en) | Novel heteroaryl carboxamides, their production and their use as a medicament | |
| CN116891447B (zh) | 一类trpv1拮抗剂、制备方法及其在制备治疗疼痛药物中的应用 | |
| WO2024125346A1 (zh) | 氘代的4-苯基哌啶-4-醇类化合物的制备及其用途 | |
| HK1203936B (en) | Dimethyl-benzoic acid compounds useful for the treatment of inflammatory conditions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160316 Termination date: 20210620 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |